Interestingly, G0S2 mutations were not reported in 1102 gliomas among TCGA WHO grade II–IV gliomas (Fig 1D), supporting the notion that G0S2 is epigenetically silenced in gliomas harboring IDH1 mutations. Here, IDH1 is linked to central nervous system cancer.